Responses
Neonatal and Paediatric Pharmacists Group 23rd Annual Conference Eastwood Hall, Nottingham
Posters
P35 An experience of switching paediatric inflammatory bowel disease patients on infliximab therapy to the biosimilar ‘remsima’
Compose a Response to This Article
Other responses
No responses have been published for this article.